{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T13:15:04Z","timestamp":1758460504934,"version":"3.44.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["GM103801","GM136430"],"award-info":[{"award-number":["GM103801","GM136430"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Espana Ministerio de Ciencia e Innovacion","doi-asserted-by":"publisher","award":["BFU2015-69092"],"award-info":[{"award-number":["BFU2015-69092"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.neuropharm.2021.108632","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T13:28:39Z","timestamp":1622813319000},"page":"108632","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Therapeutic concentrations of varenicline increases exocytotic release of catecholamines from human and rat adrenal chromaffin cells in the presence of nicotine"],"prefix":"10.1016","volume":"195","author":[{"given":"Amanda","family":"Jim\u00e9nez-Pompa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Sanz-L\u00e1zaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arik J.","family":"Hone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lola","family":"Rueda-Ruzafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Medina-Polo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Gonz\u00e1lez-Enguita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Bl\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Crist\u00f3bal","family":"de los R\u00edos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Michael McIntosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3315-9715","authenticated-orcid":false,"given":"Almudena","family":"Albillos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.neuropharm.2021.108632_bib1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1476-5381.2011.01213.x","article-title":"Stable expression and functional characterization of a human nicotinic acetylcholine receptor with \u03b16\u03b22 properties: discovery of selective antagonists","volume":"163","author":"Capelli","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108632_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-015-2055-0","article-title":"Combination therapy of varenicline with nicotine replacement therapy is better than varenicline alone: a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Chang","year":"2015","journal-title":"BMC Publ. Health"},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108632_bib3","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0022-3565(24)36376-1","article-title":"Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h\u03b12\u03b22, h\u03b12\u03b24, h\u03b13\u03b22, h\u03b13\u03b24, h\u03b14\u03b22, h\u03b14\u03b24 and h\u03b17 expressed in xenopus oocytes","volume":"280","author":"Chavez-Noriega","year":"1997","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"10","key":"10.1016\/j.neuropharm.2021.108632_bib4","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1021\/jm050069n","article-title":"Varenicline: an \u03b14\u03b22 nicotinic receptor partial agonist for smoking cessation","volume":"48","author":"Coe","year":"2005","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.neuropharm.2021.108632_bib5","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1046\/j.1460-9568.2003.02669.x","article-title":"Molecular biology and electrophysiology of neuronal nicotinic receptors of rat chromaffin cells","volume":"17","author":"Di Angelantonio","year":"2003","journal-title":"Eur. J. Neurosci."},{"issue":"12","key":"10.1016\/j.neuropharm.2021.108632_bib6","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1177\/0091270006292624","article-title":"Multiple\u2010dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers","volume":"46","author":"Faessel","year":"2006","journal-title":"J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.neuropharm.2021.108632_bib7","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1164\/rccm.201706-1204OC","article-title":"Cardiovascular and neuropsychiatric events after varenicline use for smoking cessation","volume":"197","author":"Gershon","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108632_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.296.1.47","article-title":"Varenicline, an \u03b14\u03b22 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial","volume":"296","author":"Gonzales","year":"2006","journal-title":"Jama"},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108632_bib9","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0009-9236(97)90124-7","article-title":"Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine","volume":"62","author":"Gourlay","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"issue":"35","key":"10.1016\/j.neuropharm.2021.108632_bib10","doi-asserted-by":"crossref","first-page":"25428","DOI":"10.1074\/jbc.M113.482059","article-title":"Positional scanning mutagenesis of alpha-conotoxin PeIA identifies critical residues that confer potency and selectivity for alpha6\/alpha3beta2beta3 and alpha3beta2 nicotinic acetylcholine receptors","volume":"288","author":"Hone","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.neuropharm.2021.108632_bib11","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1124\/mol.115.100982","article-title":"\u0391-conotoxins identify the \u03b13\u03b24* subtype as the predominant nicotinic acetylcholine receptor expressed in human adrenal chromaffin cells","volume":"88","author":"Hone","year":"2015","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108632_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/jnc.13883","article-title":"Therapeutic concentrations of varenicline in the presence of nicotine increase action potential firing in human adrenal chromaffin cells","volume":"140","author":"Hone","year":"2017","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2021.108632_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/jnc.14966","article-title":"Expression of \u03b13\u03b22\u03b24 nicotinic acetylcholine receptors by rat adrenal chromaffin cells determined using novel conopeptide antagonists","author":"Hone","year":"2020","journal-title":"J. Neurochem."},{"issue":"5","key":"10.1016\/j.neuropharm.2021.108632_bib14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.7326\/0003-4819-152-5-201003020-00021","article-title":"Varenicline and pheochromocytoma","volume":"152","author":"Hukkanen","year":"2010","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108632_bib15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jama.296.1.56","article-title":"Efficacy of varenicline, an \u03b14\u03b22 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial","volume":"296","author":"Jorenby","year":"2006","journal-title":"Jama"},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108632_bib16","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1177\/0091270010372388","article-title":"Single\u2010and multiple\u2010dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy Japanese adult smokers","volume":"51","author":"Kikkawa","year":"2011","journal-title":"J. Clin. Pharmacol."},{"issue":"23","key":"10.1016\/j.neuropharm.2021.108632_bib18","doi-asserted-by":"crossref","first-page":"9655","DOI":"10.1021\/jm401254c","article-title":"Characterization of a novel \u03b1-conotoxin TxID from conus textile that potently blocks rat \u03b13\u03b24 nicotinic acetylcholine receptors","volume":"56","author":"Luo","year":"2013","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108632_bib19","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/mol.106.025130","article-title":"Varenicline is a partial agonist at \u03b14\u03b22 and a full agonist at \u03b17 neuronal nicotinic receptors","volume":"70","author":"Mihalak","year":"2006","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108632_bib20","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0003-2697(90)90287-J","article-title":"Separation and culture of living adrenaline-and noradrenaline-containing cells from bovine adrenal medullae","volume":"185","author":"Moro","year":"1990","journal-title":"Anal. Biochem."},{"issue":"9","key":"10.1016\/j.neuropharm.2021.108632_bib21","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nmeth782","article-title":"Analysis of exocytotic events recorded by amperometry","volume":"2","author":"Mosharov","year":"2005","journal-title":"Nat. Methods"},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108632_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1752-1947-9-29","article-title":"Extended varenicline treatment in a severe cardiopathic cigarette smoker: a case report","volume":"9","author":"Munarini","year":"2015","journal-title":"J. Med. Case Rep."},{"issue":"6","key":"10.1016\/j.neuropharm.2021.108632_bib23","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1111\/j.1471-4159.2007.04932.x","article-title":"Key role of the nicotinic receptor in neurotransmitter exocytosis in human chromaffin cells","volume":"103","author":"P\u00e9rez\u2010Alvarez","year":"2007","journal-title":"J. Neurochem."},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108632_bib24","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/j.1476-5381.2011.01596.x","article-title":"Pharmacological characterization of native \u03b17 nicotinic ACh receptors and their contribution to depolarization\u2010elicited exocytosis in human chromaffin cells","volume":"165","author":"P\u00e9rez\u2010Alvarez","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108632_bib25","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1096\/fj.11-190223","article-title":"Native \u03b16\u03b24* nicotinic receptors control exocytosis in human chromaffin cells of the adrenal gland","volume":"26","author":"P\u00e9rez\u2010Alvarez","year":"2012","journal-title":"Faseb. J."},{"key":"10.1016\/j.neuropharm.2021.108632_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e2856","article-title":"Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis","volume":"344","author":"Prochaska","year":"2012","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.neuropharm.2021.108632_bib27","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2125.2009.03520.x","article-title":"Population pharmacokinetic analysis of varenicline in adult smokers","volume":"68","author":"Ravva","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108632_bib34","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.109.869008","article-title":"Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial","volume":"121","author":"Rigotti","year":"2010","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108632_bib28","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.neuropharm.2006.10.016","article-title":"Pharmacological profile of the \u03b14\u03b22 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid","volume":"52","author":"Rollema","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2021.108632_bib29","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.2147\/DDDT.S92268","article-title":"Evaluation of the cardiovascular effects of varenicline in rats","volume":"9","author":"Sel\u00e7uk","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"issue":"12","key":"10.1016\/j.neuropharm.2021.108632_bib30","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1503\/cmaj.110218","article-title":"Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis","volume":"183","author":"Singh","year":"2011","journal-title":"CMAJ (Can. Med. Assoc. J.)"},{"issue":"6","key":"10.1016\/j.neuropharm.2021.108632_bib31","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.neuropharm.2012.07.022","article-title":"Impact of human D398N single nucleotide polymorphism on intracellular calcium response mediated by \u03b13\u03b24\u03b15 nicotinic acetylcholine receptors","volume":"63","author":"Tammim\u00e4ki","year":"2012","journal-title":"Neuropharmacology"},{"issue":"23","key":"10.1016\/j.neuropharm.2021.108632_bib32","doi-asserted-by":"crossref","first-page":"10754","DOI":"10.1073\/pnas.88.23.10754","article-title":"Temporally resolved catecholamine spikes correspond to single vesicle release from individual chromaffin cells","volume":"88","author":"Wightman","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"22","key":"10.1016\/j.neuropharm.2021.108632_bib33","doi-asserted-by":"crossref","first-page":"6628","DOI":"10.1021\/bi7004202","article-title":"Discovery, synthesis, and structure activity of a highly selective alpha7 nicotinic acetylcholine receptor antagonist","volume":"46","author":"Whiteaker","year":"2007","journal-title":"Biochemistry"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821001866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821001866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:16:10Z","timestamp":1758438970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390821001866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":33,"alternative-id":["S0028390821001866"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108632","relation":{},"ISSN":["0028-3908"],"issn-type":[{"type":"print","value":"0028-3908"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic concentrations of varenicline increases exocytotic release of catecholamines from human and rat adrenal chromaffin cells in the presence of nicotine","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108632","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108632"}}